Supraphysiologic Testosterone Therapy in the Treatment of Prostate Cancer: Models, Mechanisms and Questions
Since Huggins defined the androgen-sensitive nature of prostate cancer (PCa), suppression of systemic testosterone (T) has remained the most effective initial therapy for advanced disease although progression inevitably occurs. From the inception of clinical efforts to suppress androgen receptor (AR...
Main Authors: | Osama S. Mohammad, Michael D. Nyquist, Michael T. Schweizer, Stephen P. Balk, Eva Corey, Stephen Plymate, Peter S. Nelson, Elahe A. Mostaghel |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2017-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/9/12/166 |
Similar Items
-
Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer
by: Hung-Ming Lam, et al.
Published: (2018-05-01) -
Mechanisms of Androgen Receptor Agonist- and Antagonist-Mediated Cellular Senescence in Prostate Cancer
by: Miriam Kokal, et al.
Published: (2020-07-01) -
How do we define “castration” in men on androgen deprivation therapy?
by: Sarin Itty, et al.
Published: (2020-01-01) -
Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer
by: Steven K. Nordeen, et al.
Published: (2021-08-01) -
Testosterone Deficiency Caused by Castration Modulates Mitochondrial Biogenesis Through the AR/PGC1α/TFAM Pathway
by: Can Liu, et al.
Published: (2019-05-01)